Lupin receives USFDA approval for generic Xenazine Tablets

23 Apr 2018 Evaluate

Lupin has received final approval for its Tetrabenazine Tablets, 12.5 mg and 25 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Valeant Pharmaceuticals North America, LLC’s Xenazine Tablets, 12.5 mg and 25 mg.

Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC’s Xenazine Tablets, 12.5 mg and 25 mg. It is indicated for the treatment of chorea associated with Huntington's disease.

Tetrabenazine Tablets, 12.5 mg and 25 mg had annual sales of approximately $288.1 million in the US (IQVIA MAT Jan 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2139.40 -26.70 (-1.23%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×